| Literature DB >> 27262595 |
Bradley R Kossmann1, Monica Abdelmalak2, Sophia Lopez2, Gabrielle Tender2, Chunli Yan1, Yves Pommier2, Christophe Marchand3, Ivaylo Ivanov4.
Abstract
Tyrosyl-DNA phosphodiesterase 2 (TDP2) processes protein/DNA adducts resulting from abortive DNA topoisomerase II (Top2) activity. TDP2 inhibition could provide synergism with the Top2 poison class of chemotherapeutics. By virtual screening of the NCI diversity small molecule database, we identified selective TDP2 inhibitors and experimentally verified their selective inhibitory activity. Three inhibitors exhibited low-micromolar IC50 values. Molecular dynamics simulations revealed a common binding mode for these inhibitors, involving association to the TDP2 DNA-binding cleft. MM-PBSA per-residue energy decomposition identified important interactions of the compounds with specific TDP2 residues. These interactions could provide new avenues for synthetic optimization of these scaffolds.Entities:
Keywords: Inhibitor; Rational drug design; TDP2; Tyrosyl-DNA phosphodiesterase 2; Virtual screening
Mesh:
Substances:
Year: 2016 PMID: 27262595 PMCID: PMC4939481 DOI: 10.1016/j.bmcl.2016.05.065
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823